Pilot Synovial Fluid Molecular/Stem Cell Response to PRP in Knee Osteoarthritis: Clinical & Imaging Outcome Correlation
NCT02468492 is a phase early 1 interventional trial sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center. As of 21 Nov 2026, it is completed. It studies Platelet Rich Plasma in Knee Osteoarthritis. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 30 Sept 2014 and a primary completion date of 30 Nov 2015.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02468492 |
| Status | Completed |
| Phase | Phase Early 1 |
| Study type | Interventional trial |
| Lead sponsor | Hunter Holmes Mcguire Veteran Affairs Medical Center |
| Enrollment | 18 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Knee Osteoarthritis |
| Drugs | Platelet Rich Plasma |
| Start | 30 Sept 2014 |
| Primary completion | 30 Nov 2015 |
| Study completion | 30 Nov 2015 |
| Last update posted | 16 Aug 2017 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Lance L Goetz, MD
Hunter Holmes McGuire VAMC
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hunter Holmes Mcguire Va Medical Center
Richmond
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02468492
Each answer restates registry values shown on this page.
What is NCT02468492?
NCT02468492 is a phase early 1 interventional trial sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center. It studies Platelet Rich Plasma in Knee Osteoarthritis.
Who leads NCT02468492?
The registry names Lance L Goetz, MD (principal investigator, Hunter Holmes McGuire VAMC) as the overall official.
Where does NCT02468492 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02468492 study?
The registered drug and biological interventions are Platelet Rich Plasma.
When did NCT02468492 end?
The registry lists a primary completion date of 30 Nov 2015 and a study completion date of 30 Nov 2015. The sponsor last updated the record on 16 Aug 2017.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.